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ABSTRACT
Background: Galectin-3, a biomarker of inﬂammation and ﬁbrosis, can be associated with
renal and myocardial damage and dysfunction in patients with acute heart failure (AHF).
Methods and Results: We retrospectively analyzed 790 patients with AHF who were enrolled
in the AKINESIS study. During hospitalization, patients with galectin-3 elevation (> 25.9 ng/
mL) on admission more commonly had acute kidney injury (assessed by KDIGO criteria), renal
tubular damage (peak urine neutrophil gelatinase-associated lipocalin [uNGAL] > 150 ng/dL)
and myocardial injury ( 20% increase in the peak high-sensitivity cardiac troponin I [hs-cTnI]
values compared to admission). They less commonly had  30% reduction in B-type natriuretic
peptide from admission to last measured value. In multivariable linear regression analysis,
galectin-3 was negatively associated with estimated glomerular ﬁltration rate and positively
associated with uNGAL and hs-cTnI. Higher galectin-3 was associated with renal replacement
therapy, inotrope use and mortality during hospitalization. In univariable Cox regression analysis, higher galectin-3 was associated with increased risk for the composite of death or rehospitalization due to HF and death alone at 1 year. After multivariable adjustment, higher
galectin-3 levels were associated only with death.
Conclusions: In patients with AHF, higher galectin-3 values were associated with renal dysfunction, renal tubular damage and myocardial injury, and they predicted worse outcomes. (J
Cardiac Fail 2022;00:1 9)
Key Words: acute heart failure, galectin-3, acute kidney injury, renal tubular damage, myocardial injury, prognosis.
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Renal dysfunction is 1 of the most common comorbidities for patients with heart failure (HF). An acute
deterioration in kidney function is commonly
observed in patients with acutely decompensated
HF (AHF) and may portend poor prognoses.1 Conversely, acute kidney injury (AKI) can induce cardiac
dysfunction and damage through several pathways,
such as volume overload, neurohormonal activation,
inﬂammation, ﬁbrosis, and oxidative stress.2,3 This
cross-talk between the heart and kidney is termed
cardiorenal syndrome (CRS), and there is growing
evidence that circulating cytokines involved in
inﬂammation and ﬁbrosis play a crucial role.1,4
Galectin-3 (Gal-3) is a biomarker produced by macrophages after organ injury.5 Mouse models have
shown that following AKI, Gal-3 is produced in the
kidney and promotes local inﬂammation and ﬁbrosis and is released into the systemic circulation,
inducing cardiac dysfunction and injury.6,7 Therefore, the Gal-3 pathway may be associated with
both renal and cardiac dysfunction or damage in
patients with AHF. However, relationships between
Gal-3 and CRS have not been fully investigated in
patients with AHF.
The Acute Kidney Injury Neutrophil gelatinaseassociated lipocalin (NGAL) Evaluation of Symptomatic Heart FaIlure Study (AKINESIS) was a prospective
observational study of patients with AHF and
included repeated sampling of biomarkers of renal
glomerular function (creatinine), renal tubular
injury (NGAL), inﬂammation and ﬁbrosis (Gal-3),
and myocardial congestion and damage (B-type
natriuretic damage [BNP] and high-sensitivity cardiac troponin I [hs-cTnI]).8 In this analysis, we aimed
to investigate whether Gal-3 expression is associated
with renal and myocardial dysfunction and portends
worse outcomes in patients with AHF.

Methods
Study Population

This is a post hoc analysis of AKINESIS, which
enrolled 927 patients with AHF at 16 sites in the
United States and Europe from January 2011
through September 2013.8 Each center’s institutional review board approved the study. Patients
must have received or planned treatment with intravenous diuretics. Patients with acute coronary syndrome were excluded. Among the 927 patients
enrolled in the original AKINESIS study, 24, 93, 13, 3,
and 4 lacked measurements of Gal-3, uNGAL, hscTnI, BNP, and estimated glomerular ﬁltration rate
(eGFR) on admission, respectively, leaving 790
patients in the current analysis.

Supplementary Table 1 shows the comparison of
patients included in and excluded by the study.
Male sex was more common in included patients
than in excluded patients (63% vs 54%; P = 0.046).
Other variables were not signiﬁcantly different.
Specimen Collection

Serum specimens for Gal-3, BNP and hs-cTnI
measurements and urine specimens for NGAL and
creatinine measurements were collected at 6 time
points during hospitalization. The ﬁrst specimen
was collected on the day of enrolment within 2
hours of the ﬁrst intravenous diuretic dose. The
second specimen was collected 2 6 hours later.
The 3rd, 4th and 5th specimens were collected on
hospital days 1, 2 and 3, respectively. The last specimen was collected on the day of hospital discharge. Specimens were analyzed at the core
laboratory with the ARCHITECT platform (Abbott
Laboratories, Abbott Park, IL). Details of the assay
performance are described elsewhere.9 Serum creatinine was measured each day during hospitalization at each institution's respective laboratory
facility.
Endpoints

We evaluated the relationships between Gal-3 on
admission and biomarker-deﬁned in-hospital endpoints. According to the Kidney Disease: Improving
Global Outcomes criteria, AKI stages were deﬁned
as the following: stage 1, increase in serum creatinine by  0.3 mg/dL or 1.5 2 times, compared to
the admission value; stage 2, increase in creatinine
to 2 3 times compared to admission; and stage 3,
increase in creatinine to  3 times compared to
admission, increase in serum creatinine to  4.0 mg/
dL or initiation of renal replacement therapy
(RRT).10,11 Acute renal tubular damage was deﬁned
as peak uNGAL value of > 150 ng/dL.12 Decongestion was deﬁned by a  30% reduction in the last
measured BNP compared to the admission BNP.13
Myocardial injury was deﬁned by a  20% increase
in the peak value of hs-cTnI compared to the admission value.14 We also evaluated other in-hospital
clinical endpoints, such as inotrope use, mechanical
ventilation, initiation of RRT, and mortality. Oneyear mortality and HF readmission were evaluated
as a composite endpoint and also analyzed individually.
Statistical Analysis

Continuous variables were described as means
with standard deviations or medians with 1st
and 3rd quartiles if non-normally distributed.
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Categorical variables were described as counts and
percentages. The Student t test, Mann-Whitney
test and2 test were used for group comparison, as
appropriate. Patients were classiﬁed by admission
Gal-3 > 25.9 ng/mL or  25.9 ng/mL, based on the
previous reports.15,16 Relationships between Gal-3
elevation and eGFR, uNGAL, BNP, and hs-cTnI
were analyzed by using a multivariable linear
regression model. These biomarkers were evaluated as area under the curves (AUC) of change during the ﬁrst 3 days of hospital admission. To
evaluate AUCs, individual changes in biomarkers
were virtually visualized as a curve where the xaxis shows day of admission to day 3, and y-axis
shows the value of the biomarker. Using this
approach, the AUC between each sample measurement can be calculated and added together,
resulting in an overall AUC score (unit of each
biomarker £ hour) that can be compared
across treatment groups.17 19 Baseline characteristics, such as demographics, medical histories,

medications before admission, and admission laboratory data were tested in a univariable model,
and factors with a Pvalue < 0.05 in univariable
analysis were included in the multivariable linear
regression model. Standardized beta-coefﬁcients
(b), 95% conﬁdence intervals (CIs) and variance
inﬂation factors (VIFs) of biomarkers were evaluated. Log-rank, Kaplan-Meier and Cox regression
analyses were used for 1-year clinical outcomes.
For HF readmission, the Fine-Gray model was used,
and death was treated as a competing risk. Multivariable analysis included age, race, history of
chronic obstructive pulmonary disease, systolic
blood pressure, heart rate, sodium, hemoglobin,
and blood urea nitrogen as well as biomarkers,
based on prior studies.20 23 Biomarkers were not
normally distributed, and they were log-2 transformed in regression analysis so that associations
represent the impact of a doubling in the biomarker. All statistical analyses were performed
using R x64 4.1.0 for Windows.

Table 1. Baseline Characteristics of Patients Grouped by More Than or Less Than and Equal to Admission Galectin-3 Levels
of 25.9 ng/mL

Variables
Age (years), mean (SD)
Male sex, n (%)
White, n (%)
BMI (kg/m2), mean (SD)
History of coronary artery disease, n (%)
History of myocardial infarction, n (%)
History of PCI, n (%)
History of CABG, n (%)
History of hypertension, n (%)
History of hyperlipidemia, n (%)
History of diabetes mellitus, n (%)
History of atrial ﬁbrillation, n (%)
History of COPD, n (%)
Tobacco use, n (%)
ACE-I, n (%)
ARB, n (%)
b-blocker, n (%)
Diuretics, n (%)
Shortness of breath, n (%)
Rales, n (%)
Edema, n (%)
Jugular vein distension, n (%)
Systolic BP (mmHg), mean (SD)
Heart rate (bpm), mean (SD)
Sodium (mEq/l), mean (SD)
Hemoglobin (g/dL), mean (SD)
eGFR (mL/min/1.73m2), mean (SD)
BNP (ng/L), median [IQR]
hs-cTnI (ng/L), median [IQR]
uNGAL (ng/dL), median [IQR]
Urine creatinine (mg/dL), median [IQR]
Loop diuretic dose within the ﬁrst 3 days of hospitalization (mg/day), median
[IQR]

Gal-3 > 25.9 ng/mL

Gal-3  25.9 ng/mL

P value

n = 375
72 (13)
223 (60)
258 (69)
31.2 (8.8)
190 (51)
113 (30)
92 (25)
78 (21)
307 (82)
207 (55)
183 (49)
120 (32)
99 (26)
41 (11)
161 (43)
69 (18)
275 (73)
279 (74)
267 (71)
180 (48)
295 (79)
107 (29)
137 (30)
85 (22)
138 (5)
11.4 (2.2)
49 (25)
650 [245, 1265]
30.0 [14.0, 66.4]
16.4 [5.2, 50.4]
16.4 [5.2, 50.4]
67 [40, 113]

n = 415
66 (14)
278 (67)
247 (60)
31.8 (8.8)
173 (42)
99 (23.9)
83 (20.0)
57 (14)
331 (80)
203 (49)
163 (39)
97 (23)
104 (25)
87 (21)
186 (45)
82 (20)
284 (68)
280 (68)
272 (66)
157 (38)
293 (71)
101 (24)
144 (29)
90 (23)
139 (8)
11.9 (2.5)
73 (26)
439 [202, 992]
23.1 [12.0, 51.3]
9.7 [3.8, 22.7]
9.7 [3.8, 22.7]
53 [27, 80]

<0.001
0.034
0.008
0.413
0.014
0.056
0.148
0.011
0.509
0.09
0.009
0.008
0.727
<0.001
0.644
0.693
0.152
0.039
0.103
0.005
0.012
0.209
0.001
0.004
0.069
0.001
<0.001
<0.001
0.009
<0.001
<0.001
0.001

ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; bpm, beats per minute; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; Gal-3, galectin 3; hs-cTnI, high sensitivity cardiac troponin I; IQR,
interquartile range; PCI, percutaneous coronary intervention; SD, standard deviation; uNGAL, urine neutrophil gelatinase-associated
lipocalin.
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Results
Of the 790 patients included in the study, the
mean age was 69 § 14 years, 63% were male, 46%
had coronary artery disease, and 44% had diabetes
mellitus. The mean eGFR on admission was 61 § 28
mL/min/1.73m2. The completeness of biomarkers at
each time point is shown in Supplementary Table 2.
In brief, the completeness at the 1st 5th collection
time points were 100%, 83% 89%, 80%–86%,
78%–88% and 76%–84%, respectively (Supplementary Table 2). Patients with admission Gal-3 > 25.9
ng/mL (375 patients, 47%) were older and more
likely to be female and less likely to be white
(Table 1). Coronary artery disease, coronary artery
bypass grafting, diabetes mellitus, and atrial ﬁbrillation were more prevalent, and tobacco use was less
prevalent in patients with Gal-3 > 25.9 ng/mL. They
were more likely have been treated previously with
diuretics and had rales and edema at hospital admission. Systolic blood pressure, heart rate, hemoglobin, and eGFR were lower in patients with higher
Gal-3. BNP, hs-cTnI, uNGAL, and urine creatinine
were higher in patients with higher Gal-3. These
patients received a higher total dosage of loop diuretics during the ﬁrst 3 hospital days.
During hospitalization, patients with Gal-3 >
25.9 ng/mL on admission less commonly had a

decrease in BNP  30% and more commonly had
an increase in hs-cTnI  20% and peak uNGAL values > 150 ng/dL (Fig. 1A). The incidences of AKI
stage 1, 2 and 3 were 23% (181 patients), 2% (15
patients) and 3% (26 patient), respectively, in all
patients. Patients with Gal-3 > 25.9 ng/mL more
commonly had AKI (Fig. 1B). RRT and inotrope use
were more common, and in-hospital mortality
was higher in those with Gal-3 > 25.9 ng/mL
(Fig. 1C).
When relationships between the AUCs of Gal-3
and other biomarkers were evaluated by multiple
linear regression models, Gal-3 was signiﬁcantly and
negatively associated with eGFR and positively associated with uNGAL and hs-cTnI (Fig. 2). There was no
signiﬁcant association between Gal-3 and BNP. VIFs
of biomarkers in each model were  1.27 for eGFR,
 1.64 for uNGAL,  1.66 for BNP, and  1.74 for hscTnI.
The composite endpoint was observed in 261
patients (33%); 140 patients died (18%), and 154
patients (19%) were readmitted due to HF within 1
year. Patients with admission Gal-3 > 25.9 ng/mL
had higher incidences of the composite endpoint
and mortality than those with Gal-3  25.9 ng/mL,
whereas the incidence of HF readmission was not
different between the groups (Fig. 3). Higher Gal-3
was associated with an increased risk for the

Fig. 1. Levels of galectin-3 and adverse events. A, Galectin-3 and biomarker deﬁned endpoints. Patients with admission values of Gal-3 > 25.9 ng/mL less commonly had BNP  30% decrease and more commonly had hs-cTnI  20% increase and
peak uNGAL > 150 ng/dL than those with Gal-3  25.9 ng/mL (P < 0.05 for all). B, Galectin-3 and acute kidney injury. The
incidence of AKI was higher in patients with Gal-3 > 25.9 ng/mL than those with Gal-3  25.9 ng/mL (P < 0.05). C, Galectin3 and in-hospital clinical endpoints. Renal-replacement therapy, inotrope use and in-hospital death were more frequently
observed in patients with Gal-3 > 25.9 ng/mL (P < 0.05). AKI, acute kidney injury; BNP, B-type natriuretic peptide; Gal-3,
galectin 3; hs-cTnI, high-sensitivity cardiac troponin I; uNGAL, urine neutrophil gelatinase-associated lipocalin.
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Fig. 2. Relationship between galectin-3 and other biomarkers. Standardized beta-coefﬁcient (b) of biomarkers for eGFR,
uNGAL, BNP, and hs-cTnI in multivariable linear regression models are shown. AUCs of the ﬁrst 3 days of hospitalization
were used for biomarkers (eGFR, uNGAL, BNP, hs-cTnI, and urine creatinine). For eGFR, factors included in the model were
age, gender, race, heart rate, systolic blood pressure, history of CAD, PCI, CABG, and dyslipidemia, smoking, ACE inhibitors,
hemoglobin, edema, rales, furosemide dose during the ﬁrst 3 days of hospitalization, Gal-3, uNGAL, BNP, and hs-cTnI. For
uNGAL, factors included in the model were age, gender, history of PCI, hemoglobin, edema, furosemide dose during the
ﬁrst 3 days, Gal-3, BNP, hs-cTnI, eGFR, and urine creatinine. For BNP, factors included in the model were age, gender, systolic blood pressure, body mass index, history of CAD, CABG, COPD, and diabetes mellitus, beta-blocker, hemoglobin, rales,
jugular vein distention, Gal-3, uNGAL, hs-cTnI, eGFR, and urine creatinine. For hs-cTnI, factors included in the model were
age, gender, heart rate, body mass index, history of CAD and COPD, diuretics use on admission, rales, hemoglobin, furosemide dose during the ﬁrst 3 days, Gal-3, uNGAL, BNP, and eGFR. In multivariable linear regression analysis for eGFR, VIFs of
Gal3, uNGAL, BNP and hs-cTnI were 1.23, 1.17, 1.24, and 1.27, respectively. For uNGAL, VIFs of Gal3, BNP, hs-cTnI and eGFR
were 1.51, 1.26, 1.21, and 1.64, respectively. For BNP, VIFs of Gal3, uNGAL, hs-cTnI, and eGFR were 1.61, 1.56, 1.12, and
1.66, respectively. For hs-cTnI, VIFs of Gal3, uNGAL, BNP, and eGFR were 1.55, 1.20, 1.29, and 1.74, respectively. ACE-I,
angiotensin-converting-enzyme inhibitor; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CAD,
coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; Gal-3,
galectin 3; hs-cTnI, high sensitivity cardiac troponin I; PCI, percutaneous coronary intervention; uNGAL, urine neutrophil
gelatinase-associated lipocalin; VIF, variance inﬂation factor.

composite endpoint (hazard ratio [HR] of log2 Gal-3
1.36, 95% CI 1.16–1.60; P < 0.001) and mortality (HR
1.87, 95% CI 1.55–2.25; P < 0.001) in univariable
analysis and for mortality in multivariable analysis
(adjusted HR 1.61, 95% CI 1.27– 2.04; P < 0.001)
Table 2. Gal-3 was not associated with HF rehospitalization (HR 0.97, 95% CI 0.77–1.23; P = 0.803).
Discussion
In this analysis of patients with AHF, we investigated a relationship between Gal-3 and cardiorenal
biomarkers and adverse events. We found that
patients with higher Gal-3 levels more commonly
had lower eGFRs and renal tubular injuries, congestion and myocardial damage. Gal-3 values were signiﬁcantly related to renal glomerular dysfunction,
tubular injury and myocardial damage, independent
of possible confounding factors. Further, Gal-3 elevation was associated with in-hospital adverse
events, including RRT, inotrope use and mortality.

Gal-3 elevation also predicated worse 1-year outcomes, especially mortality.
Gal-3 has been reported to be associated with
ﬁbrosis of the kidney, and elevated Gal-3 values
predicted rapid decline of renal glomerular function and progressive renal impairment.24 In the
current analysis, higher Gal-3 values may reﬂect
progressive glomerular dysfunction; patients with
higher Gal-3 values had worse renal function on
admission and were more likely to have AKI after
hospitalization. Moreover, Gal-3 elevation was
also associated with renal tubular damage,
deﬁned by an elevation in uNGAL, a known biomarker of acute renal tubular damage. In patients
with AHF, a decrease in GFR with treatment after
hospitalization is not generally associated with
actual renal tubular injury and can be a functional
and hemodynamic change in renal function.25
Therefore, the association of Gal-3 with both renal
functional deterioration and tubular injury is of
signiﬁcant importance. Values of Gal-3 and uNGAL
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Fig. 3. Galectin-3 and clinical outcomes. Patients with Gal-3 > 25.9 ng/mL on admission had higher incidence of the
composite of death or readmission due to heart failure and mortality within 1 year (P = 0.01 for the composite endpoint;
P < 0.01 for mortality; P = 0.875 for HF rehospitalization).

Table 2. Hazard Ratios for Clinical Events at 1 Year
Univariable

Death or HF rehospitalization
log2Gal-3
Death
log2Gal-3
HF rehospitalization
log2Gal-3

Multivariable

HR

95% CI

P value

Adjusted HR

95% CI

P value

1.36

1.16 1.60

< 0.001

1.09

0.89 1.32

0.397

1.87

1.55 2.25

< 0.001

1.61

1.27 2.04

< 0.001

0.97

0.77-1.23

0.803

0.80

0.58 1.10

0.160

Multivariable Cox regression analysis included age, race, history of chronic obstructive pulmonary disease, systolic blood pressure, heart
rate, sodium, hemoglobin, BUN, BNP, hscTnI and uNGAL. Values of Gal3, BNP, hs-cTnI and uNGAL were log-2 transformed.
BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CI, conﬁdence interval; Gal-3, galectin 3; hs-cTnI, high sensitivity cardiac troponin I; HR, hazard ratio; uNGAL, urine neutrophil gelatinase-associated lipocalin.

may be affected by changes in GFR because these
biomarkers are cleared by the kidney, but these
relationships remained signiﬁcant after adjustment for GFR and other possible confounders.24,26
In the event of AKI, macrophage inﬁltration with
increased Gal-3 expression is observed in the renal
tubular cells, and that is associated with renal
inﬂammation and ﬁbrosis.7 Gal-3 may play an
important role in renal dysfunction and injury,
and its assessment may help to predict kidneyrelated adverse events in patients with AHF.
We also showed that Gal-3 was independently
associated with an elevation in hs-cTnI. Hs-cTn elevation is commonly observed in patients with AHF and

is associated with worse prognoses.23 Proposed
mechanisms for troponin elevation and myocardial
injury in AHF include myocardial stretch from volume overload, subendocardial ischemia with left
ventricular hypertrophy, elevated intracardiac pressures, and arrhythmia. Although systemic inﬂammation and ﬁbrosis are also thought to induce
myocardial damage, that has not been fully elucidated in a large-scale clinical cohort.27 In the current
study, Gal-3 was independently associated with hscTnI after adjustment for possible confounders. The
confounding factors in the multivariable model
included older age, heart rate and hemoglobin, suggesting that the association between hs-cTnI and
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Gal-3 was independent of known causes of acute
myocardial injury.28 Moreover, this association can
also be independent of hemodynamic deterioration
due to AHF and CRS because the model included
diuretic dosage and eGFR and BNP levels. Furthermore, several studies have shown that AKI may
induce remote cardiac damage through the Gal-3
pathway.7,29 31 In a mouse model with AKI,
increased expression of Gal-3 in renal tubular cells
led to an increase in circulating Gal-3 levels, promoting Gal-3 expression in the heart and resulting in
myocardial ﬁbrosis and dysfunction.7 Our study cannot show as direct a link as this animal model shows,
but our ﬁndings are in line with the concept that
Gal-3 reﬂects or even induces adverse outcomes
when AKI occurs in AHF.
Additionally, multiple studies have shown that
Gal-3 levels are prognostic for cardiovascular outcomes in patients with HF.15,32,33 In the current analysis, patients with elevated Gal-3 more commonly
had in-hospital adverse events, such as receiving RRT
and inotrope and death. Also, Gal-3 values predicted
1-year mortality, independent of BNP, hscTnI,
uNGAL, and other confounding factors. Our results
suggest that Gal-3 may help to identify patients at
increased risk for adverse cardiorenal events during
initial hospital admission and at high risk for mortality after hospitalization, independent of known predictors of poor prognosis in patients with AHF.
Limitations

This is a post hoc analysis of a prospective cohort
study. Although we showed associations between biomarkers of kidney injury, inﬂammation and ﬁbrosis,
and myocardial damage, causal relationships could
not be determined in this observational study. Identiﬁed or unidentiﬁed confounders may have inﬂuenced
the results of multivariable analyses. We considered
factors that could affect the value of biomarkers in
multivariable liner regression analysis, but changes in
blood pressure and acid/base balance were lacking
and, thus, were not included in the model. Unfortunately, data concerning echocardiography was lacking
in 41% of the patients, so they were not included in
the current analysis. The missing values of biomarkers,
especially at the later time point, could have affected
the results. Causes of HF and years from diagnosis
were not recorded either. Kidney injury was evaluated
only by uNGAL, and other biomarkers were not measured. Other common biomarkers of inﬂammation,
such as C-reactive protein and interleukin-6, were not
measured either.
Conclusions
In patients with AHF, higher Gal-3 values were
associated with renal dysfunction, renal tubular

damage and myocardial injury. An increased expression of Gal-3 predicted worse in-hospital and 1-year
clinical outcomes. The assessment of Gal-3 on admission may help to identify patients who are at high
risk for kidney-related adverse events, myocardial
injury during hospitalization and poor prognoses.
Lay Summary
Among patients hospitalized for acute heart failure (AHF), those with galectin-3 elevation on admission more commonly had renal dysfunction, renal
tubular damage and myocardial injury during hospitalization. Higher galectin-3 levels were associated
with renal-replacement therapy, inotrope use and
in-hospital mortality. Galectin-3 elevation was also
associated with increased risk for the composite of
death or HF rehospitalization and death alone at 1
year. In patients with AHF, the assessment of galectin-3 may help to identify patients who are at high
risk for kidney-related adverse events, myocardial
injuries and poor prognoses.
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